{"organizations": [], "uuid": "b4cbf1dde1e4f13dc311dc866cfd901a7733e4ce", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-horizon-pharma-sees-krystexxa-fy-2/brief-horizon-pharma-sees-krystexxa-fy-2018-sales-up-more-than-50-percent-idUSL8N1P330W", "country": "US", "domain_rank": 408, "title": "BRIEF-Horizon Pharma Sees Krystexxa FY 2018 Sales Up More Than 50 Percent", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T20:28:00.000+02:00", "replies_count": 0, "uuid": "b4cbf1dde1e4f13dc311dc866cfd901a7733e4ce"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-horizon-pharma-sees-krystexxa-fy-2/brief-horizon-pharma-sees-krystexxa-fy-2018-sales-up-more-than-50-percent-idUSL8N1P330W", "ord_in_thread": 0, "title": "BRIEF-Horizon Pharma Sees Krystexxa FY 2018 Sales Up More Than 50 Percent", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "horizon pharma plc", "sentiment": "negative"}, {"name": "brief-horizon pharma sees krystexxa", "sentiment": "negative"}, {"name": "krystexxa", "sentiment": "negative"}, {"name": "pharma plc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Horizon Pharma Plc:\n* HORIZON PHARMA SEES KRYSTEXXA FY 2018 SALES UP MORE THAN 50 PERCENT\n* HORIZON PHARMA PLC - INCREASING ITS ESTIMATED PEAK ANNUAL NET SALES EXPECTATIONS FOR EACH MEDICINE TO MORE THAN $750 MILLION\n* HORIZON PHARMA PLC INCREASES PEAK NET SALES GUIDANCE FOR KEY GROWTH DRIVERS AND ANNOUNCES RHEUMATOLOGY AND ORPHAN PIPELINE DEVELOPMENTS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:28:00.000+02:00", "crawled": "2018-01-09T16:56:55.037+02:00", "highlightTitle": ""}